China Approves EGFR×HER3 Bispecific ADC for Previously Treated Recurrent or Metastatic Nasopharyngeal Cancer
Quick Answer / What Happened
According to Xinhua News, China's National Medical Products Administration has approved Baili Tianheng's independently developed EGFR×HER3 bispecific antibody-drug conjugate, iza-bren, also known in China as Yizekang, for adult patients with recurrent or metastatic nasopharyngeal cancer who have failed at least two prior lines of systemic chemotherapy and PD-1/PD-L1 inhibitor treatment. The approval was reported on June 24, 2026, and is based on the PANKU-NPC 01 study.
Why This Matters
Nasopharyngeal cancer is a head and neck cancer with a distinct regional pattern. Xinhua described it as more common in southern China, Southeast Asia, and parts of Africa, and noted its close relationship with Epstein-Barr virus infection. For patients with metastatic nasopharyngeal cancer after later-line treatment failure, the report described available treatment options as very limited, with significant unmet clinical need.
That context is why this approval matters beyond a single drug announcement. It is connected to a disease area that is especially relevant to Chinese-speaking regions and parts of Southeast Asia, where more families may be actively looking for advanced oncology options after standard pathways become limited.
What The Source Reported About Iza-Bren
Xinhua reported that iza-bren is an EGFR×HER3 bispecific ADC, or bispecific antibody-drug conjugate. The report described it as a first-in-class, new-concept EGFR×HER3 bispecific ADC and said it is the first such drug to enter a Phase III registrational clinical study in this class.
According to the report, iza-bren targets EGFR and/or HER3 and delivers a cytotoxic payload. The source described this mechanism as designed to move beyond the limits of traditional chemotherapy and single-target drugs, opening a new pathway for more precise cancer treatment.
CareNavigator is summarizing Xinhua's report here. Patients should not read this as a direct treatment recommendation or as a statement that the drug is suitable for any individual case.
The Clinical Study Behind The Approval
Xinhua stated that the approval is based on the PANKU-NPC 01 study, which the report described as the world's first confirmatory Phase III clinical trial for later-line nasopharyngeal cancer treatment, according to the report. The report said the study was conducted with 55 medical centers across China.
The report also stated that the study results were selected for the Late Breaking Abstract session at ESMO 2025 and were published simultaneously in The Lancet.
In the Xinhua report, Professor Ma Jun of Sun Yat-sen University Cancer Center described the approval as marking a new era of bispecific ADC treatment for later-line recurrent and metastatic nasopharyngeal cancer. Xinhua quoted him as saying that patients after multiple prior treatment failures had often faced a situation with few available drugs, and that iza-bren had been listed by NCCN and CSCO guidelines as a recommended treatment option.
Why Southeast Asian Patients May Pay Attention
The source specifically notes the regional relevance of nasopharyngeal cancer in Southeast Asia. For Southeast Asian patients and families, this kind of China oncology update may be important for a simple reason: some advanced treatment developments in China are emerging in disease areas that are also regionally meaningful outside China.
This does not mean every Southeast Asian patient can or should travel to China for this therapy. It does mean that, for selected patients with recurrent or metastatic nasopharyngeal cancer, China may be a destination worth including in a careful treatment-option review, especially when later-line choices are limited locally or when families want to understand whether China-based oncology pathways may be relevant.
What This Does NOT Mean
This approval does not mean iza-bren is suitable for every patient with nasopharyngeal cancer. The reported indication is specific: adult patients with recurrent or metastatic nasopharyngeal cancer after failure of at least two prior lines of systemic chemotherapy and PD-1/PD-L1 inhibitor treatment.
It also does not mean access, timing, cost, clinical benefit, or hospital acceptance can be assumed. Treatment relevance depends on diagnosis, prior therapies, disease status, biomarker and clinical review where relevant, drug availability, hospital pathway, patient condition, and the treating team's judgment.
Broader China Oncology Innovation Signal
Xinhua also reported that iza-bren is the first Chinese bispecific ADC drug to go overseas. According to the report, Baili Tianheng entered into a collaboration with Bristol Myers Squibb in December 2023 for iza-bren, with the total transaction value reaching up to USD 8.4 billion, which Xinhua described as setting, according to the report, a global ADC single-drug outbound licensing record.
The report further stated that, as of June 2026, iza-bren had entered more than 40 clinical trials across tumor types in China and the United States. Reported investigational areas include lung cancer, esophageal squamous cell carcinoma, and triple-negative breast cancer, with applications for esophageal squamous cell carcinoma and triple-negative breast cancer accepted by China's Center for Drug Evaluation.
For international readers, this is one more example of why China's oncology landscape is increasingly important to watch: not only because of hospital capacity, but because Chinese companies, regulators, clinical investigators, and cancer centers are contributing to drug development in high-need disease areas.
How CareNavigator Can Help Patients Evaluate Relevance
CareNavigator can help patients and families turn a news update into practical questions. For a patient with recurrent or metastatic nasopharyngeal cancer, that may include organizing prior treatment history, pathology, imaging, immunotherapy and chemotherapy records, current disease status, and the family's decision question.
CareNavigator can then help identify whether a China-based oncology review may be worth exploring and coordinate the next step with appropriate medical providers when relevant. CareNavigator does not determine eligibility or treatment strategy. Those decisions belong to qualified doctors and responsible medical institutions.
Tell Us Your Situation
Tell us your situation. If your family is dealing with recurrent or metastatic nasopharyngeal cancer and wants to understand whether China has relevant oncology pathways to review, CareNavigator can help you prepare the case, ask better questions, and coordinate next steps with appropriate medical providers.
Related CareNavigator Resources
- Why China
- How CareNavigator Helps
- Pathways Decision Library
- China Advanced Treatment Updates
- China Treatment Navigation Guide
- Overseas Treatment Options
Source-Led Update Note
This article summarizes publicly available reporting from Xinhua News. It is not CareNavigator's independent clinical assessment of iza-bren, EGFR×HER3 bispecific ADC therapy, or nasopharyngeal cancer treatment. It should not be read as medical advice for any individual patient. Patient eligibility, risks, benefits, availability, cost, and treatment decisions should be assessed by licensed clinicians and the responsible medical institution.
Primary source: Xinhua News, published on 2026-06-24. Original URL: https://www.news.cn/health/20260624/cf504ce7163b4f1280a0a83da4afdfcc/c.html